Susquehanna initiates coverage on Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) with a Positive. Price target $4.

Susquehanna analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE